UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | April 1, 2016 |
OPKO Health, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 001-33528 | 75-2402409 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
4400 Biscayne Blvd., Miami, Florida | 33137 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | (305) 575-4100 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 1, 2016, the Compensation Committee of the Board of Directors (the Committee) of OPKO Health, Inc. (the Company) held a meeting to review certain compensation matters for the Companys executive officers and non-executive employees. At the meeting, the Committee granted stock options to the Companys named executive officers to purchase the number of shares of the Companys common stock set forth opposite their names below. The stock options vest ratably over four years and expire on the tenth anniversary of the grant date.
Name | Title | Stock Options | ||||||
Phillip Frost |
Chairman/Chief Executive
Officer |
500,000 | ||||||
Jane H. Hsiao |
Vice Chairman/Chief Technical Officer |
450,000 | ||||||
Steven D. Rubin |
Executive Vice President |
450,000 | ||||||
Adam Logal |
Senior Vice President/Chief Financial
Officer |
250,000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc. | ||||
April 1, 2016 | By: |
Adam Logal
|
||
|
||||
Name: Adam Logal | ||||
Title: Senior Vice President-Chief Financial Officer |